ACCUSTEM SCIENCES, INC.
Income Statement
| Line Item | Aug 2026 | Jun 2026 | May 2026 | Apr 2026 | Mar 2026 | Dec 2025 | Nov 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $98.4K | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $43.7K | — | — | $119.5K | — | — | $72.7K |
| SG&A Expense | — | $307.3K | — | — | $366.4K | — | — | $327.2K |
| Operating Income | — | $-252.6K | — | — | $-485.9K | — | — | $-399.9K |
| Operating Margin | — | -256.7% | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | $-485.9K | — | — | $-399.9K |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | — | $-252.6K | — | — | $-485.9K | — | — | $-399.9K |
| Net Margin | — | -256.7% | — | — | — | — | — | — |
| EPS (Basic) | — | $-0.02 | — | — | $-0.03 | — | — | $-0.02 |
| EPS (Diluted) | — | $-0.02 | — | — | $-0.03 | — | — | $-0.02 |
| Shares Outstanding (Basic) | 16.1M | 16.1M | 16.1M | 16.1M | 16.1M | 16.1M | 16.1M | 16.1M |
| Shares Outstanding (Diluted) | 16.1M | 16.1M | 16.1M | 16.1M | 16.1M | 16.1M | 16.1M | 16.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |